These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 15585609)

  • 1. Radioimmunotherapy for non-Hodgkin's lymphoma.
    Friedberg JW
    Clin Cancer Res; 2004 Dec; 10(23):7789-91. PubMed ID: 15585609
    [No Abstract]   [Full Text] [Related]  

  • 2. Dosimetry and radioimmunotherapy of non-Hodgkin's lymphoma.
    Postema EJ
    J Nucl Med; 2004 Dec; 45(12):2126-7; author reply 2127. PubMed ID: 15585492
    [No Abstract]   [Full Text] [Related]  

  • 3. Radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.
    Whelton S
    Nurse Pract; 2007 Dec; 32(12):35-8. PubMed ID: 18043410
    [No Abstract]   [Full Text] [Related]  

  • 4. Radiolabeled immunotherapy in non-Hodgkin's lymphoma treatment: the next step.
    Otte A; van de Wiele C; Dierckx RA
    Nucl Med Commun; 2009 Jan; 30(1):5-15. PubMed ID: 19020470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conventional treatments for non-Hodgkin's lymphoma: the need for new therapies.
    White CA; Wiseman G
    J Nucl Med; 1999 Nov; 40(11):1967-8. PubMed ID: 10565795
    [No Abstract]   [Full Text] [Related]  

  • 6. Practical and clinical benefits of radioimmunotherapy lead to advantages in cost-effectiveness in the treatment of patients with non-Hodgkin's lymphoma.
    Otte A; Thompson SL
    Nucl Med Commun; 2006 Oct; 27(10):753-6. PubMed ID: 16969255
    [No Abstract]   [Full Text] [Related]  

  • 7. Is high-dose radioimmunotherapy needed in non-Hodgkin's lymphoma? For.
    Behr TM
    Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1248-54. PubMed ID: 12418465
    [No Abstract]   [Full Text] [Related]  

  • 8. The expanding frontier of radioimmunotherapy of relapsed Non-hodgkin's lymphoma.
    Kozuch P; Grossbard ML
    Clin Lymphoma; 2000 Sep; 1(2):158-9. PubMed ID: 11707826
    [No Abstract]   [Full Text] [Related]  

  • 9. New directions in radioimmunotherapy of non-Hodgkin's lymphoma.
    DeNardo GL
    Clin Lymphoma; 2004 Oct; 5 Suppl 1():S4. PubMed ID: 15498148
    [No Abstract]   [Full Text] [Related]  

  • 10. Radioimmunotherapy effective first-line treatment for non-Hodgkin's lymphoma.
    Oncology (Williston Park); 2000 Jul; 14(7):1009, 1039. PubMed ID: 10929588
    [No Abstract]   [Full Text] [Related]  

  • 11. Will radioimmunotherapy survive?
    Zelenetz AD
    Clin Adv Hematol Oncol; 2007 Oct; 5(10):782-4. PubMed ID: 17998896
    [No Abstract]   [Full Text] [Related]  

  • 12. Commentary: let the tail wag the dog: the case for radioimmunotherapy of low-grade follicular lymphoma.
    Plastaras JP; Glatstein E; Schuster SJ
    Oncologist; 2008 Jun; 13(6):655-6. PubMed ID: 18586920
    [No Abstract]   [Full Text] [Related]  

  • 13. Establishing a radioimmunotherapy outpatient care clinic for Non-Hodgkin's lymphoma.
    Hendrix C; de Leon C
    Semin Oncol Nurs; 2002 Feb; 18(1 Suppl 1):22-9. PubMed ID: 11878048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of pre-treatment radiation absorbed dose estimation for radioimmunotherapy of non-Hodgkin's lymphoma.
    Eary JF; Krohn KA; Press OW; Durack L; Bernstein ID
    Nucl Med Biol; 1997 Oct; 24(7):635-8. PubMed ID: 9352534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretargeted radioimmunotherapy of non-Hodgkin's lymphoma: best of both worlds?
    Boerman OC; Oyen WJ; Corstens FH
    Cancer Biother Radiopharm; 2000 Feb; 15(1):1-5. PubMed ID: 10740647
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs).
    DeNardo GL
    Semin Nucl Med; 2005 Jul; 35(3):202-11. PubMed ID: 16098294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioimmunotherapy of hematological cancer: problems and progress.
    Jurcic JG; Scheinberg DA
    Clin Cancer Res; 1995 Dec; 1(12):1439-46. PubMed ID: 9815942
    [No Abstract]   [Full Text] [Related]  

  • 18. Advances in radioimmunotherapy in the age of molecular engineering and pretargeting.
    Sharkey RM; Goldenberg DM
    Cancer Invest; 2006 Feb; 24(1):82-97. PubMed ID: 16466997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective study of the separate predictive capabilities of 18[F]-FDG-PET and molecular response in patients with relapsed indolent non-Hodgkin's lymphoma following treatment with iodine-131-rituximab radio-immunotherapy.
    Bishton MJ; Hicks RJ; Westerman DA; Prince MH; Wolf M; Seymour JF
    Haematologica; 2008 May; 93(5):789-90. PubMed ID: 18450737
    [No Abstract]   [Full Text] [Related]  

  • 20. Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.
    Lindén O; Hindorf C; Cavallin-Ståhl E; Wegener WA; Goldenberg DM; Horne H; Ohlsson T; Stenberg L; Strand SE; Tennvall J
    Clin Cancer Res; 2005 Jul; 11(14):5215-22. PubMed ID: 16033839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.